photo walkheader_zpsd5bunpmi.png

Category Archives: Pancreatic Cancer Clinical Trials

Tarceva Plus Gemcitabine After Surgery for Pancreatic Cancer ?

Gress and colleagues from the University of Marburg in Germany published the results of a Phase II trial in the October 2013 issue of the Annals of Oncology, the official journal of the European Society for Medical Oncology. They did a prospective multi-center study of 76 pancreatic cancer (ductal adenocarcinoma of the pancreas) patients over […]

FDA Grants Orphan Status for the CRS-207 Vaccine with GVAX Immunotherapy for Pancreatic Cancer

In an interesting step with intriguingly complex promise, the Office of Orphan Products Development of the U.S. Food and Drug Administration recently designated the immunotherapy CRS-207 as having orphan drug status for use in sequential combination with the GVAX Pancreas biologic for the treatment of pancreatic cancer (ductal adenocarcinoma of the pancreas). Both of these […]

FOLFIRINOX (Minus Irinotecan) for Gemcitabine-refractory Pancreatic Cancer

Since the promising article on the 4-drug 5-FU led FOLFIRINOX regimen for metastatic pancreatic cancer (ductal adenocarcinoma of the pancreas) per the May 12, 2011 article in the New England Journal of Medicine, this treatment approach has emerged as a solid first-line option.  In the ensuing months there have been a number of studies exploring […]

Page 4 of 6« First...23456
Facebook
Facebook